<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623245</url>
  </required_header>
  <id_info>
    <org_study_id>11714</org_study_id>
    <nct_id>NCT01623245</nct_id>
  </id_info>
  <brief_title>Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy</brief_title>
  <acronym>Amylo</acronym>
  <official_title>Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thibaud Damy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Cardiology Society</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac amyloidosis are related to the accumulation of fibrillar proteins in the
      extracellular leading to disruption of the cardiac tissue architecture. Amyloidosis in
      transthyretin (TTR) are the most common hereditary amyloidosis but remain poorly studied at
      heart. This is serious and deadly. The prevalence of TTR amyloidosis is probably
      underestimated in hypertrophic cardiomyopathy (HCM) often of unknown etiology because of the
      lack of systematic implementation of myocardial biopsy because of their side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A systematic screening of TTR mutations within the MHC would diagnose cardiac amyloidosis in
      TTR and improve the care of patients and their families.

      The detection of this disease is important because this disease is fatal and a new treatment
      to prevent the accumulation of TTR is now available (Tafamidis). This drug has proved
      effective in stabilizing neurological damage.

      Depending on the number of patient with cardiac amyloidosis in TTR detected, the prospect
      will begin a clinical trial to test the effectiveness of a new treatment to prevent the
      increase in mass of the left ventricle wall objectified resonance nuclear Magnetic.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of ATTRm mutations</measure>
    <time_frame>1 day</time_frame>
    <description>Number of ATTRm mutations detected in a large population of patients with HCM.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genotype and clinical factors</measure>
    <time_frame>1 day</time_frame>
    <description>Identify clinical factors associated with biological and echocardiographic different HCM genotypes.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">294</enrollment>
  <condition>Cardiac Amyloidosis</condition>
  <condition>Amyloidosis in Transthyretin (TTR)</condition>
  <condition>Hypertrophic Cardiomyopathy (HCM)</condition>
  <arm_group>
    <arm_group_label>Hypertrophic Cardiomyopathy</arm_group_label>
    <description>In the population of Hypertrophic Cardiomyopathy patients, patients suffering from a cardiac amyloidosis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      10 mL of whole blood in EDTA tube
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is that of patients with hypertrophic cardiomyopathy in France whose
        origin has not yet been determined.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with cardiomyopathy defined by an ultrasound thickness of the left ventricle
             &gt;= 13 mm if familial form or &gt;= 15 mm if sporadic form.

          -  Patients with a signed consent authorizing the specific blood test for genetic
             sequencing to look for abnormal TTR gene

        Exclusion Criteria:

          -  Patients with a diagnosis of cardiomyopathy already determined or related already
             diagnosed.

          -  Significant aortic stenosis (≤ 1 cm ²)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thibaud DAMY</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Christoph DC, Boese D, Johnson KT, Schlosser TW, Hunold P, Baba HA, Erbel R, Philipp S. Heart failure and cardiac involvement as isolated manifestation of familial form of transthyretin amyloidosis resulting from Val30Met mutation with no clinical signs of polyneuropathy. Circ Heart Fail. 2009 Sep;2(5):512-5. doi: 10.1161/CIRCHEARTFAILURE.109.853697.</citation>
    <PMID>19808383</PMID>
  </reference>
  <reference>
    <citation>Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003 Aug 7;349(6):583-96. Review.</citation>
    <PMID>12904524</PMID>
  </reference>
  <reference>
    <citation>Mörner S, Hellman U, Suhr OB, Kazzam E, Waldenström A. Amyloid heart disease mimicking hypertrophic cardiomyopathy. J Intern Med. 2005 Sep;258(3):225-30.</citation>
    <PMID>16115295</PMID>
  </reference>
  <reference>
    <citation>Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997 Feb 13;336(7):466-73.</citation>
    <PMID>9017939</PMID>
  </reference>
  <reference>
    <citation>Planté-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, Said G. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007 Aug 14;69(7):693-8.</citation>
    <PMID>17698792</PMID>
  </reference>
  <reference>
    <citation>Planté-Bordeneuve V. [The diagnosis and management of familial amyloid polyneuropathy]. Rev Neurol (Paris). 2006 Nov;162(11):1138-46. Review. French.</citation>
    <PMID>17086153</PMID>
  </reference>
  <reference>
    <citation>Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009 Sep 29;120(13):1203-12. doi: 10.1161/CIRCULATIONAHA.108.843334. Epub 2009 Sep 14.</citation>
    <PMID>19752327</PMID>
  </reference>
  <reference>
    <citation>Said G, Planté-Bordeneuve V. Familial amyloid polyneuropathy: a clinico-pathologic study. J Neurol Sci. 2009 Sep 15;284(1-2):149-54. doi: 10.1016/j.jns.2009.05.001. Epub 2009 May 24.</citation>
    <PMID>19467548</PMID>
  </reference>
  <reference>
    <citation>Saraiva MJ. Sporadic cases of hereditary systemic amyloidosis. N Engl J Med. 2002 Jun 6;346(23):1818-9.</citation>
    <PMID>12050344</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2012</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>French Cardiology Society</investigator_affiliation>
    <investigator_full_name>Thibaud Damy</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

